To the full analysis
Legend Biotech stock: growth
LEGNLegend Biotech reported $1.03B in revenue for fiscal 2025, up 64% on the prior year, up 68.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
60.3%
per year from 2017 to 2025, per share 53.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 68.8% | 60.3% |
| Revenue per share | 54.5% | 53.8% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $23.59M | $9.37M | −$3.26M |
| 2018 | $49.13M | −$2.78M | $286.66M |
| 2019 | $61.8M | −$101.59M | −$122.24M |
| 2020 | $75M | −$266.37M | −$253.29M |
| 2021 | $68.83M | −$403.58M | −$243.87M |
| 2022 | $117.01M | −$446.35M | −$223.56M |
| 2023 | $285.14M | −$518.25M | −$416M |
| 2024 | $627.24M | −$177.03M | −$158.14M |
| 2025 | $1.03B | −$296.8M | −$168.04M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2021)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.